Major Depressive Disorder: Rethinking and Understanding Recent Discoveries

Section I. Re-thinking depression from a network perspective.- Chapter 1. Phenotype network and brain structural covariance network of major depression.- Chapter 2. Task MRI-based functional brain network of major depression.- Chapter 3. White matter-based structural brain network of major depression.- Chapter 4. The application of a machine learning-based brain MRI approach in major depression.- Chapter 5. Resting state functional MRI in major depression.- Chapter 6. Development of neuroimaging-based biomarkers in depressive disorder.- Section II. Current diagnostic and neurobiological issues.- Chapter 7. Challenges and strategies for current classifications of depressive disorders: proposal for future diagnostic standards.- Chapter 8. Epigenetics: a missing link between early life stress and depression.- Chapter 9. Glia- neuron communications and gut-brain axis in depression.- Chapter 10. Apoptosis and proliferation markers in major depression.- Chapter 11. A load to find clinically useful biomarkers for depression.- Chapter 12. Pharmacogenomic tests for diagnosis and treatment prediction in depression.- Section III. Current specific treatments for depression.- Chapter 13. Biofeedback and neurofeedback for depression: a critical review.- Chapter 14. Cognitive behavioral therapy and mindfulness based cognitive therapy for depressive disorders.- Chapter 15. Acceptance Commitment Therapy (ACT) for major depressive disorder.- Chapter 16. Neurostimulation therapies in depressive disorders.- Chapter 17. Ketamine in major depression: New rapid antidepressant.- Chapter 18. Psychodynamic therapy in depressive disorders.- Chapter 19. Well-being therapy in depressive disorders.- Chapter 20. Complementary and alternative medicine in the treatments of depressive disorders.- Chapter 21. Current psychopharmacology algorithm for major depressive disorder.- Section IV. Promising future treatments for depression.- Chapter 22. Novel psychopharmacology for depressive disorders.- Chapter 23. Cannabinoid agents for depressive disorders.- Chapter 24. Virtual Reality for the treatment of depressive disorders.- Chapter 25. Epigenetic Therapy in depressive disorders.- Chapter 26. Induced pluripotent stem (iPS) cells technology: potential therapeutic targets for depression.- Chapter 27. Vaccination and immunotherapy for major depression.- Chapter 28. Psychedelic Medicines in major depression: progress and future challenges.- Chapter 29. Precision Psychiatry: Biomarker guided Tailored Therapy for Effective Treatment and Prevention in major depression.